Table 1.
Characteristics of patients enrolled in the two treatment groups.
| CG | IG | |
|---|---|---|
| Patients (No) | 41 | 30 |
| Age | ||
| Mean | 59.71 | 52.10 |
| SD (y/o) | 9.92 | 11.26 |
| Median | 59 | 53 |
| Range | (39-80) | (32-75) |
| Surgery | ||
| Quadrantectomy | 41 (100%) | 30 (100%) |
| LAD | 25 (61%) | 18 (60%) |
| S.Linf | 16 (39%) | 12 (40%) |
| Hystologic type | ||
| Ductal | 35 (85%) | 22 (73%) |
| Lobular | 2 (5%) | 1 (4%) |
| Others | 4 (10%) | 7 (23%) |
| Chemiotherapy | ||
| Yes | 19 (46.4%) | 15 (50%) |
| No | 22 (53.6%) | 15 (50%) |
| Hormone therapy | ||
| Yes | 31 (75.6%) | 21 (70%) |
| No | 10 (24.4%) | 9 (30%) |
| Breast volume | ||
| > 500 cc | 71 (75.5%) | 46 (71%) |
| ≤ 500 cc | 23 (24.5%) | 19 (29%) |
| Breast maximum dose | ||
| ≤ 107% | 8 (19.5%) | 4 (13.3%) |
| > 107% < 110% | 26 (63.5%) | 19 (63.4%) |
| ≥ 110% | 7 (17%) | 7 (23.3%) |
CG: control group IG: Group Ixor®